Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children with T-ALL, potentially enabling clinicians to make faster, personalized ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood ...
The family of an 11-year-old cancer survivor is using their non-profit to help families going through the hardships of cancer ...
Tempus AI and Blood Cancer United have launched an AI powered real world registry for pediatric acute myeloid leukemia. The registry is designed to centralize clinical and patient reported data to ...
Infant leukemia linked to rearrangements of the NUTM1 gene has shown remarkably strong outcomes on current therapy in international datasets, including 100% four-year event-free survival in one ...
Two years ago, Lianna Munir started spiking fevers and having fainting spells. At first doctors thought Munir, then 6, may have strep or a viral infection. But even after multiple trips to the ...
Fifth-grader Levi Buxman of Wooster has amassed more than 4,000 beads signifying various aspects of treatment for B-cell ...
A rare form of leukemia known as TCF3::HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most ...